The ESC 2018 has seen a lot of significant clinical trial results being declared which will definitely change practice at least for those who are progressive and open-minded. On CT that I bringing to your notice here is on Aspirin's ability (or inability) to prevent CV events in those with moderate-risk.
Name : ARRIVE Objective: To evaluate aspirin vs placebo in moderate-CV-risk patients (10-year CHD-risk 10-20%) Design : Randomized, Parallel (Placebo), Blind 12,546 patients- randomized to Aspirin 100 mg (6,270) and Placebo (6,276) 60-month follow-up Inclusion Criteria : Men (=>55 yrs), Women (=>60 yrs) => 3 CV Risk factors (dyslipidemia, smoking, HT, family h/o CV disease) Exclusion Criteria : DM, stroke, heart disease (CHF, MI, coronary/vascular Intervention, arrhythmias) Concomitant anti-platelet, anti-coagulant, NSAID H/O gastro/duodenal ulcer of GI bleeding Results : Composite CV…
